You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
New Therapy for Ocular Herpes Simplex Stromal Infection
SBC: Redox Pharmaceutical Topic: N/AHSV-l is the major infectious cause of corneal blindness in the United States. Redox has synthesized transition metal complexes (CTC compounds) exhibiting potent in vitro activity against herpes group viruses. Significantly, the mode of action of these novel compounds differs from currently available antiviral nucleoside analogs. One CTC compound exhibits pronounced efficacy in the topical therapy ...
SBIR Phase II 1996 Department of Health and Human Services -
Severity of Drug Disorders--Clinician Scales
SBC: Research Assessment Associates Topic: N/ANo semi-structured clinical interview currently exists that (a) assesses the severity of DSM-IV andsubstance use disorders and (b) is designed to be sensitive to changes in clinical status. The Psychfor Substance and Mental Disorders (PRISM) is a clinician-administered, semi-structured interview thprovides reliable diagnoses of drug and alcohol disorders. Preliminary psychometric analyses of PRIt ...
SBIR Phase II 1996 Department of Health and Human Services -
Measurement of Hemodialysis Access Flow & Recirculation
SBC: TRANSONIC SYSTEMS, INC. Topic: N/AWe recently introduced a novel ultrasound indicator dilution method which has the potential to becoeconomical measurement tool of hemodialysis access flow and recirculation during patient dialysis. Wtechnologies in an animal model, in collaboration with researchers at the NYS College of VeterinaryUniversity; support clinical evaluations in key hemodialysis treatment centers in order to establishth ...
SBIR Phase II 1996 Department of Health and Human Services -
Postexposure Prophylaxis Against HIV 1 by Cd4 Igg2
SBC: PROGENICS PHARMACEUTICALS, INC. Topic: N/AAn individual who is exposed to HIV-1 contaminated blood or other bodily fluids runs a significantbecoming infected with the virus. The goal of post-exposure prophylaxis is to protect exposed indivianticipated infection. The major clinical settings for HIV-1 post- exposure prophylactic therapy inctransmission as a result of accidental needle-stick injuries sustained by health care workers and vein ...
SBIR Phase II 1996 Department of Health and Human Services -
Environmental Assessment Protocol for Special Care Units
SBC: Innovative Desings And Topic: N/AResearch is providing increasing evidence of the potential therapeutic effectsof the physical environment for people with dementia in long-term care settings. Despite this, facilitieshave limited options for learning how to create more supportive environments. Hence few facilities areincorporating those environmental features cited as important in the research literature. Existing optionsare eithe ...
SBIR Phase II 1996 Department of Health and Human Services -
Rectal Foam for the Delivery of an Antiepileptic Drug
SBC: Sciarra Laboratories, Inc. Topic: N/AWe will support performance of a research study to address the feasibility for developing anexperimental metered delivery foam preparation for the rectal delivery of an antiepileptic drug for usein patients unable to receive medication via oral and/or intravenous routes. The end product of thiscontract is a final report, which shall summarize results of the research work conducted hereunder.Specif ...
SBIR Phase II 1996 Department of Health and Human Services -
Development of an Antidote for E Coli 0157--H7 Verotoxin
SBC: OPHIDIAN PHARMACEUTICALS, INC. Topic: N/AE. coli Ol57:H7 is an emerging food-borne pathogen with substantial morbidity and mortality.There are an estimated 20,000 cases of E. coli 0157:H7 infection per year in the United States.However, only 11 states require reporting of the cases to the State Health Department; hence, the actualnumber of cases is likely to be much higher. Twenty-two percent of children acquiring E. coli Ol57:H7infectio ...
SBIR Phase II 1996 Department of Health and Human Services -
Title missing
SBC: Appolo Research Corp. Topic: N/AN/A
SBIR Phase II 1996 Department of Health and Human Services -
Inhibition of The HIV-1 REV Transactivator
SBC: ONCOGENE SCIENCE, INC. Topic: N/AAcquired Immunodeficiency Syndrome (AIDS), a disease affecting millions of individuals worldwide, has a high incidence of patient mortality. The etiological agent of this disease, the infectious retrovirus HIV-l, has proven refractory to therapeutic intervention. The drugs used in the clinic today only target the viral reverse transcriptase. At best, such drugs temporarily delay disease progressio ...
SBIR Phase II 1996 Department of Health and Human Services -
Novel Polymorphic Markers for Genetic Analyses
SBC: PROMEGA CORP. Topic: N/AOur research will identify and develop a new type of polymorphic DNA marker that will allowsimplification and acceleration of genetic analyses. These multiplex-compatible amplifiable markers willhave the advantage of simplified analysis versus current PCR-based marker systems, allowing detectionin a new agarose gel format rather than requiring denaturing polyacrylamide gels. The markers will alsob ...
SBIR Phase II 1996 Department of Health and Human Services